WALTHAM, Mass., Nov. 03, 2016 (GLOBE NEWSWIRE) -- Interleukin Genetics, Inc. (OTCQB:ILIU) a life science company focused on the genetics of chronic inflammation, today unveiled the ILUSTRA™ Inflammation Management Program. The program targets individuals at elevated risk for severe periodontitis due to a genetic tendency to over-produce inflammation. Under supervision of a licensed dentist or physician, ILUSTRA is offered by employers and through select insurance carriers as an enhanced benefit that has potential to provide significant health and economic value by improving the management of chronic inflammation.
ILUSTRA incorporates three components: 1) a simple yet technologically advanced genetic risk test; 2) targeted education to healthcare professionals to individualize care plans; and 3) an 18-month subscription to the ILUSTRA Engagement Platform, a digital program to support plan members and drive behavior change. The ILUSTRA brand reflects the expanded program positioning and replaces the PerioPredict® brand name.
“We are extremely excited about the launch of ILUSTRA, which is the result of several months of careful market research and testing,” said Mark Carbeau, Chief Executive Officer of Interleukin Genetics. “Customers said they want a turnkey program that delivers real impact. Our comprehensive approach delivers on this need by improving patients’ lives through better management of inflammation and has the potential to significantly reduce costs for plan sponsors. The ILUSTRA program provides a promising product to drive sales, and reflects our passion to make genetic insights actionable.”
“Inflammation is strongly implicated in the onset and progression of several chronic diseases such as diabetes and cardiovascular disease,” said Kenneth Kornman, DDS, PhD, President and Chief Scientific Officer. “Evidence supports the value of managing patients by integrating both medical and dental science, and we see ILUSTRA as advancing care for chronic diseases through precision Dental-Medical Integration.”
About the ILUSTRA Inflammation Management Program
The ILUSTRA Inflammation Management Program is designed to transform the management of inflammation. The program utilizes a genetic test to identify patients at elevated risk for developing severe periodontal disease due to a genetic tendency to over-produce inflammation. Such individuals may benefit from enhanced dental care to lower their systemic inflammatory burden by preventing and treating gingivitis and periodontitis. The program integrates educational outreach to the patient’s care team and provides reminders and content to patients to drive engagement. The ILUSTRA Inflammation Management Program is made available to employees in covered health plans under the supervision of a licensed dentist or physician. The ILUSTRA test is run solely in Interleukin’s CLIA-certified lab in suburban Boston. For more information, visit www.ILUSTRA.com.
About Interleukin Genetics
Interleukin Genetics, Inc. (OTCQB:ILIU) develops and markets proprietary genetic tests for chronic inflammatory diseases and health-related conditions, with significant expertise in metabolism and inflammation. Our tests provide information that is not otherwise available to empower individuals and their healthcare providers to manage their health and wellness through genetics-based insights and actionable guidance. Interleukin Genetics leverages its research, intellectual property, and genetic panel development expertise in inflammation and metabolism to identify individuals whose risk for certain chronic disease may be increased due to variants in one or more genes, which can enable a more targeted approach to the individual’s healthcare. The company markets its tests through healthcare professionals, partnerships with health and wellness companies, and other distribution channels. Interleukin Genetics’ lead products include its proprietary ILUSTRA Inflammation Management Program, a turnkey program that utilizes a simple genetic test to easily identify patients at elevated risk for developing severe periodontal disease, due to a genetic tendency to over-produce inflammation, and its Inherent Health® line of genetic tests. Interleukin Genetics is headquartered in suburban Boston and operates an on-site, state-of-the-art DNA testing laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA). For more information, please visit www.ilgenetics.com.
Certain statements contained herein are “forward-looking” statements, including, but not limited to, statements that our ILUSTRA Inflammation Management Program has potential to provide significant health and economic value by improving the management of chronic inflammation and that certain individuals may benefit from enhanced dental care to lower their systemic inflammatory burden by preventing and treating gingivitis and periodontitis . Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, those risks and uncertainties described in Interleukin’s annual report on Form 10-K for the year ended December 31, 2015, and other filings with the Securities and Exchange Commission. Interleukin disclaims any obligation or intention to update these forward-looking statements.
Source:Interleukin Genetics, Inc.